0.03%外用他克莫司用于激素依赖型复发性泡性角结膜炎的维持治疗

Topical Tacrolimus 0.03% for Maintenance Therapy in Steroid-Dependent, Recurrent Phlyctenular Keratoconjunctivitis.

作者信息

Yoon Chang Ho, Kim Mee Kum, Oh Joo Youn

机构信息

Department of Ophthalmology, Seoul National University Hospital, Jongno-gu, Seoul, Korea.

Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Jongno-gu, Seoul, Korea.

出版信息

Cornea. 2018 Feb;37(2):168-171. doi: 10.1097/ICO.0000000000001440.

DOI:10.1097/ICO.0000000000001440

PMID:29309358

Abstract

PURPOSE

To evaluate the efficacy of topical tacrolimus 0.03% as steroid-free maintenance therapy in young patients with severe, recurrent phlyctenular keratoconjunctivitis (PKC).

METHODS

The medical records of 6 eyes of 5 patients (4 children and 1 young adult) with recurrent, steroid-dependent PKC were reviewed. The patients were treated with combined application of topical steroids and tacrolimus 0.03% in the active phase and maintained on topical tacrolimus alone after remission.

RESULTS

The clinical signs, symptoms, and visual acuities resolved in all patients after 25.2 ± 16.9 days of combined treatment with steroids and tacrolimus. After disease remission, the patients were maintained on topical tacrolimus 0.03% once daily alone for 8.4 ± 4.7 months, and no recurrence occurred during 10.6 ± 1.9 months of follow-up. Tacrolimus was successfully discontinued in 2 patients without further recurrence. There were no ocular side effects related to the use of topical tacrolimus.

CONCLUSIONS

Topical tacrolimus 0.03% was effective in maintaining long-term remission in patients with recurrent, steroid-dependent PKC.

摘要

目的

评估0.03%他克莫司局部用药作为无类固醇维持疗法对重度复发性泡性角结膜炎（PKC）年轻患者的疗效。

方法

回顾了5例（4例儿童和1例青年成人）复发性、依赖类固醇的PKC患者6只眼的病历。患者在急性期接受局部类固醇和0.03%他克莫司联合应用治疗，缓解后仅使用局部他克莫司维持治疗。

结果

在类固醇和他克莫司联合治疗25.2±16.9天后，所有患者的临床体征、症状和视力均得到缓解。疾病缓解后，患者单独每日一次使用0.03%他克莫司局部用药维持治疗8.4±4.7个月，在10.6±1.9个月的随访期间未发生复发。2例患者成功停用他克莫司且未进一步复发。未出现与局部使用他克莫司相关的眼部副作用。